Frazier Life Sciences
Signal active
Investment Firm
Overview
Frazier Life Sciences IX is a venture capital fund. Frazier Life Sciences invests in and builds companies developing and commercializing novel therapeutics at all stages, from company formation to public.
Highlights
Founded
1991
Industry
Employees
11-50
Investment
33
Lead Investment
9
Exits
17
Stages
Late Stage Venture, Early Stage Venture, Seed
Investor Type
Venture Capital
Location
United States, North America
Contact Information
Social
Profile Resume
Frazier Life Sciences, established in 1991 and headquartered in United States, North America., specializes in Late Stage Venture, Early Stage Venture, Seed investments across Biotechnology, Health Care, Wellness, Therapeutics, Financial Services, Venture Capital, Finance, Business Development, Consumer, Asset Management. The organization boasts a portfolio of 31 investments, with an average round size of $93.7M and 17 successful exits. Their recent investments include MBX Biosciences, Norwest Venture Partners, New Enterprise Associates, Wellington Management, T. Rowe Price. The highest investment round they participated in was $332.5B. Among their most notable exits are MBX Biosciences and Norwest Venture Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Employees
N/A
Investment portfolio
Frazier Life Sciences has made 33 investments. Their most recent investment was on Aug 05, 2024, when MBX Biosciences raised $63.5M.
Frazier Life Sciences has made 2 diversity investments. Their most recent diversity investment was on Apr 07, 2022, when Trevi Therapeutics raised $55.0M.
investments
33
Diversity investments
2
Lead investments
9
Number of exits
17
Investments
33
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jun 14, 2024 | Disc Medicine | Biotechnology | 178.0M |
| Jun 28, 2024 | Savara Pharmaceuticals | Biotechnology | 100.0M |
| Jul 16, 2024 | Scorpion Therapeutics | Biotechnology | 150.0M |
| Aug 05, 2024 | MBX Biosciences | Biotechnology | 63.5M |
Exits
17
Funding Timeline
Funding rounds
33
Investors
0
Funds
0
Funding Rounds
33
Frazier Life Sciences has raised 33 rounds. Their latest funding was raised on Aug 05, 2024 from a Series C - MBX Biosciences round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jun 14, 2024 | Post-IPO Equity - Disc Medicine | - | 178.0M | - |
| Jun 28, 2024 | Post-IPO Equity - Savara Pharmaceuticals | - | 100.0M | - |
| Jul 16, 2024 | Series C - Scorpion Therapeutics | - | 150.0M | - |
| Aug 05, 2024 | Series C - MBX Biosciences | - | 63.5M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
N/A
Recent Activity
There is no recent news or activity for this profile.